PERIPHERAL T-CELL LYMPHOMA
Clinical trials for PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo for rare blood cancer shows early promise, but trial halted
Disease control TerminatedThis early-phase trial tested a combination of two drugs (parsaclisib and chidamide) in 12 people with a rare type of blood cancer called peripheral T-cell lymphoma that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for side eff…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control TerminatedThis early-phase study tested a new medicine, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The st…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Experimental lymphoma combo trial halted early
Disease control TerminatedThis study tested a drug called selinexor combined with chemotherapy or another drug (tislelizumab) in 56 adults with relapsed or hard-to-treat T-cell or NK-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, so res…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated May 11, 2026 20:54 UTC